| DB ID | MyCo_2326 |
| Title | Optimization of a commercial Histoplasma galactomannan EIA test in a population from an endemic area of histoplasmosis in southern Brazil |
| Year | 2022 |
| PMID | 36513799 |
| Fungal Diseases involved | Disseminated Histoplasmosis |
| Associated Medical Condition | HIV-AIDS |
| Genus | None |
| Species | None |
| Organism | None |
| Ethical Statement | None |
| Site of Infection | None |
| Opportunistic invasive | None |
| Sample type | Body fluid |
| Sample source | None |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | GM |
| Biomarker Full Name | Galactomannan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Brazil |
| Cohort | A retrospective study was carried out including all patients investigated for DH using the Q-¬ HGM EIA, during the period from March 2021 to May 2022 in a tertiary hospital (Hospital Universitário Dr. Miguel Riet Correa Jr., Rio Grande -¬ HU-¬ FURG/ EBSERH), located in southern Rio Grande do Sul, Brazil. The study included 264 urinary samples, from 226 patients, tested by Q-¬ HGM EIA, being most of the specimens from PLHIV (86%, n = 228). |
| Cohort No. | 226 |
| Age Group | None |
| P Value | None |
| Sensitivity | 0.88 |
| Specificity | 0.987 |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | None |
| Technique | ELISA |
| Analysis Method | ELISA Based |
| ELISA kits | IMMY's Clarus® Histoplasma GM enzyme immunoassay (EIA) Kit |
| Assay Data | FDA Approved Clarus® Histoplasma GM enzyme immunoassay |
| Validation Techniques used | ELISA |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
